Edwards Lifesciences Corp

$69.28
(as of Sep 16, 3:59 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Edwards Lifesciences Corp

Stock Price
$69.29
Ticker Symbol
EW
Exchange
NYSE

Industry Information for Edwards Lifesciences Corp

Sector
Healthcare
Industry
Medical Devices

Company Description for Edwards Lifesciences Corp

Country
USA
Full Time Employees
19,800

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Fundamentals for Edwards Lifesciences Corp

Market Capitalization
$41,276,444,672
EBITDA
$2,028,300,032
Dividends per Share
P/E Ratio
26.98
Forward P/E Ratio
26.74
Earnings per Share
$2.54
Earnings per Share Estimate Next Year
$2.74
Profit Margin
23.74%
Shares Outstanding
602,400,000
Percent Owned by Insiders
0.90%
Percent Owned by Institutions
85.71%
52-Week High
$96.12
52-Week Low
$58.93

Technical Indicators for Edwards Lifesciences Corp

50-Day Moving Average
$72.83
200-Day Moving Average
$81.43
RSI
47.97
2.2

Analyst Ratings for Edwards Lifesciences Corp

Strong Buy
9
Buy
5
Hold
16
Sell
1
Strong Sell
0

News About Edwards Lifesciences Corp

Sep 11, 2024, 6:05 AM EST
One thing we could say about the analysts on Edwards Lifesciences Corporation (NYSE:EW) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. See more.
Sep 8, 2024, 8:00 AM EST
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' See more.
Sep 5, 2024, 11:31 AM EST
A month has gone by since the last earnings report for Globus Medical (GMED). See more.
Sep 4, 2024, 11:28 AM EST
Edwards Lifesciences, a medical device maker based in California, said it has successfully completed the sale of its Critical Care product group to BD for $4.2 billion in an all-cash transaction. See more.
Sep 4, 2024, 7:54 AM EST
Edwards Lifesciences EW has completed the sale of its Critical Care product group to Becton, Dickinson and Company BDX for $4.2 billion in an all-cash transaction. See more.